Adhera Therapeutics, Inc. - FORM 10-K - EX-10.91 - EXHIBIT 10.91 - October 10, 2012

Attached files

file filename
10-K - FORM 10-K - Adhera Therapeutics, Inc.v324618_10k.htm
EX-3.7 - EXHIBIT 3.7 - Adhera Therapeutics, Inc.v324618_ex3-7.htm
EX-21.1 - EXHIBIT 21.1 - Adhera Therapeutics, Inc.v324618_ex21-1.htm
EX-31.1 - EXHIBIT 31.1 - Adhera Therapeutics, Inc.v324618_ex31-1.htm
EX-23.1 - EXHIBIT 23.1 - Adhera Therapeutics, Inc.v324618_ex23-1.htm
EX-32.2 - EXHIBIT 32.2 - Adhera Therapeutics, Inc.v324618_ex32-2.htm
EX-31.2 - EXHIBIT 31.2 - Adhera Therapeutics, Inc.v324618_ex31-2.htm
EX-32.1 - EXHIBIT 32.1 - Adhera Therapeutics, Inc.v324618_ex32-1.htm
EX-10.77 - EXHIBIT 10.77 - Adhera Therapeutics, Inc.v324618_ex10-77.htm
EX-10.76 - EXHIBIT 10.76 - Adhera Therapeutics, Inc.v324618_ex10-76.htm
EX-10.92 - EXHIBIT 10.92 - Adhera Therapeutics, Inc.v324618_ex10-92.htm
EX-10.80 - EXHIBIT 10.80 - Adhera Therapeutics, Inc.v324618_ex10-80.htm
EX-10.81 - EXHIBIT 10.81 - Adhera Therapeutics, Inc.v324618_ex10-81.htm
EX-10.90 - EXHIBIT 10.90 - Adhera Therapeutics, Inc.v324618_ex10-90.htm
EX-10.93 - EXHIBIT 10.93 - Adhera Therapeutics, Inc.v324618_ex10-93.htm
EXCEL - IDEA: XBRL DOCUMENT - Adhera Therapeutics, Inc.Financial_Report.xls

 

EXECUTION COPY

 

AMENDMENT NO. 2 TO RESEARCH AND LICENSE AGREEMENT

 

This Amendment No. 2 (“Amendment 2”), effective as of April 1, 2011 (“Amendment 2 Effective Date”), is made by and between

 

Debiopharm S.A., a stock company duly established under the laws of Switzerland, with registered company number CH-550-0173350-8, whose registered office is at Forum “après-demain”, Chemin Messidor 5-7, 1006 Lausanne, Switzerland (“DEBIOPHARM”),

 

And

 

Marina Biotech, Inc., a company duly established under the laws of the State of Delaware, whose registered office is at 3830 Monte Villa Parkway, Bothell, Washington 98021, U.S.A. (“COMPANY”),

 

WITNESSETH:

 

Whereas, DEBIOPHARM and COMPANY are parties to that certain Research and License Agreement with an effective date of February 3, 2011, as amended by Amendment No. 1 with an effective date of March 9, 2011 (collectively, the “Agreement”); and

 

Whereas, the Parties desire to amend the Agreement as set forth herein;

 

Now, therefore, the Parties hereby agree as follows:

 

1.Unless otherwise defined herein, capitalized terms used in this Amendment shall have the meanings assigned thereto in the Agreement.

 

2.The definition of “Collaboration Targets” set forth in Section 1.1 shall be amended to read as follows:

 

“Collaboration Targets” means the target genes identified in Exhibit 1-1 plus an additional target selected by DEBIOPHARM by May 3, 2011.

 

3.Exhibit 1 shall be amended and replaced in its entirety with Exhibit 1-1, attached hereto and incorporated herein by this reference

 

4.Except as amended herein, all other terms and conditions of the Agreement shall remain in full force and effect.

 

5.This Amendment 2 may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Any signature page delivered by facsimile or electronic image transmission shall be binding to the same extent as an original signature page.

 

[Signature page follows]

 

 

CONFIDENTIALAmendment No. 2 – Research and License Agreement 
 

 

EXECUTION COPY

 

In witness whereof, the Parties hereby accept and agree to the terms and conditions of this Amendment as of the Amendment 2 Effective Date.

 

DEBIOPHARM S.A.   MARINA BIOTECH, INC.
     
By: /s/ R.Y. Mauvernay   By: /s/ J. MICHAEL FRENCH
         
Name: R.Y. Mauvernay   Name: J. MICHAEL FRENCH
         
Title:     Title: PRESIDENT & CEO

 

 

CONFIDENTIALAmendment No. 2 – Research and License Agreement 

 

Adhera Therapeutics, Inc. Reports